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sideration if the duals are treated as a homogenous group. The objective of this study 
was to compare elderly vs disabled duals across demographic, morbidity, health 
care utilization, and drug spending measures. Methods: Cross-sectional analysis 
comparing profiles of disabled (n= 90,894) and elderly (n= 126,752) fee-for-service 
beneficiaries with continuous 12-month dual-eligibility, or until alive in the 2007 
5% Medicare files. Chi-square and t-tests were conducted to measure statistically 
significant differences across measures of interest between elderly and disabled 
duals. Results: Elderly duals were more likely to be female and suffer from chronic 
conditions like CHF, while disabled duals were more likely to have mental disorders 
like depression. Disabled duals had significantly higher rates of ER use (8.4% vs 6.4%) 
and lower rate of hospitalization (31.9% vs 24.5%) than elderly duals. Compared to 
the disabled, elderly duals had significantly higher rates of Part D brand drug use 
(88% vs 81%), but lower use of drugs typically placed on Part D specialty tiers (10% 
vs 13%). Significant differences existed in the types of drug classes frequently used 
by the two groups. Large differences in spending across all types of medical services 
and drug categories across the two groups were observed. ConClusions: There 
are significant differences in demographic, morbidity, health care utilization, and 
drug spending measures across the elderly vs. disabled duals. Recognizing the dif-
ferences between sub-populations of dual eligibles is critically important and a “one 
size fits all” approach may unintentionally create hardships and be detrimental to 
the well-being of the duals.
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rAnDomizeD triAl of A Pbm venDor solution
Smith-McLallen A.1, Zhang B.2, Estes E.1, Buss W.2
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objeCtives: (1) To examine the impact of two medication review programs designed 
to decrease overall health care costs through optimizing medication therapy. The 
interventions are designed to promote proper prescribing in accordance with clini-
cal literature and national guidelines and counsel individual members with regard 
to their medication regimens; (2) To explore the use of randomized clinical trials 
to vet vendor proposed programs for improving health and reducing health care 
costs. Methods: Independence Blue Cross and their Pharmacy Benefit Manager, 
Catamaran jointly designed a randomized controlled trial to test the efficacy of 
two medication review programs. Medical and pharmacy claims data for members 
assigned to the intervention condition were analyzed daily for intervention opportu-
nities based on a complex set of rules. The rules identify members who may benefit 
from one or more of 14 potential therapy adjustments including drug-drug and 
drug-condition interactions, dose optimization, appropriateness of therapy, high 
risk medication in the elderly, and generic interchange. Once identified, Catamaran 
contacted prescribers via fax to recommend therapy adjustments. Verification of 
therapy changes were determined through claims reviews and prescriber feed-
back. Results: 39,138 members were randomly assigned to either the intervention 
or control. Results show that 28% of the clinical recommendations were adopted 
resulting in a reduction in pharmacy spend of $72,747 and a reduction in medi-
cal spend of $1 million. ConClusions: Catamaran’s medication review programs 
show significant medical and pharmacy cost savings while improving population 
health through appropriate management of prescription drugs. These programs 
are intended to help members avoid inappropriate or potentially dangerous medi-
cations, increase medication adherence, close gaps in care, optimize medication 
therapy, and lower medical costs. Moreover, we demonstrate that a collaborative 
approach to evaluating a proposed vendor solution resulted in a cost effective RCT 
that offers maximum benefit to members and the health plan.
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objeCtives: This study assessed trends in state-level, fee-for-service Medicaid 
generic and brand drug utilization and expenditures, and pharmacy reimburse-
ment rates in the period 2010-2012. Methods: Medicaid fee-for-service outpatient 
pharmacy utilization and expenditures, and reimbursement rates (ingredient cost 
and dispensing fees) for the years 2010-2012 were extracted from State-level data 
provided from the Centers for Medicare and Medicaid Services. Current dollars 
were converted to 2012 dollars using the U.S. consumer price index. Descriptive 
analyses were performed for all variables. Confidence intervals (95%) were calcu-
lated for continuous variables. Linear regression analysis was performed to assess 
the relationship between ingredient cost, dispensing fees and drug utilization. The 
significance level for variables was 0.05. Results: Fee-for-service Medicaid expen-
ditures (n= 42 states) decreased from $23.0 billion in 2010 to $18.7 billion in 2012 
(14.9% decrease) and drug utilization decreased from 351.2 to 281.4 million claims 
in the same period (19.9% decrease). Generic utilization represented 70.6% of total 
prescriptions in 2010 and 75.4% in 2012, and generic expenditures represented 17.9% 
of total expenditures in 2010 and 18.0% in 2012. The average reimbursement of 
generic drugs was $17.89 (95%CI= $16.63-$19.14) in 2010 and decreased to $16.91 
(95%CI= $14.48-$19.34) in 2012, while the average reimbursement of brand drugs 
increased from $197.34 (95%CI= $184.74-$209.94) to $235.93 (95%CI= $218.07-$253.79). 
The average pharmacy dispensing fee increased from $4.34±$1.24 to $4.60±$2.56 
for generics and from $4.10±$1.19 to $4.38±$2.58 for brands. We found no statis-
tically significant relationship between the number of claims or the total state 
expenditures, and the dispensing fee or the average ingredient cost. ConClusions: 
Pharmacy expenditures decreased in the period 2010-2012 due to a decrease in the 
volume of prescriptions and the reduction in generic prices. Differences in dispens-
ing fees and ingredient costs among Medicaid programs were independent of total 
prescription volume. Increases in generic utilization could result in substantial 
savings to Medicaid programs.
complete claims 180 days pre and 720 days post index. Biologic claim clean period 
was 180 days pre-index. SQ biologic users with reported days supplies that were 
< 7 or > 90 days were excluded. Duration of action for infusion products was based 
on package inserts. Patients were censored after a gap of at least 90 days beyond 
the next expected re-fill interval. Results describe median time to discontinuation 
(Kaplan-Meier plots) covering 720 days. A Cox regression model assessed the IV vs 
SQ hazard ratio. Results: 1830 IV and 5934 SQ patients were identified. Diagnoses 
in the IV cohort included 29.9% IBD, 50.4% RA, 3.2% PsA and 16.5% any combination 
or none. Corresponding diagnoses for the SQ cohort were 10.9%, 49.5%, 8.9% and 
30.7% respectively. IV and SQ cohorts were similar for gender and co-morbidities, 
and IV cohort was slightly older with slightly higher use of concomitant methotrex-
ate and steroids than SQ cohort in RA and PsA. Overall, median time to discontinu-
ation for IV was 388 days vs SQ at 191 days, and was significantly longer for IV vs 
SQ across all indications. Within SQ cohort, RA patients (203 days) had the longest 
persistence vs other indications. For IV cohort, it was PsA patients (471 days). IBD 
patients tended to have the shortest persistence. Cox regression showed hazard for 
SQ discontinuation 1.61(CI:1.51-1.72) times greater than for IV, controlling for age, 
gender and co-morbidities. ConClusions: IV consistently demonstrated longer 
times to discontinuation vs. SQ across indications studied.
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objeCtives: This study sought to examine the effect of pharmacists’ visits to home-
bound patients on the elimination of unused drugs. Methods: We conducted a 
survey with pharmacies throughout Japan that provided home visiting service, 
requesting their home-visiting pharmacists to respond to questions regarding 
their work with up to five homebound patients (the survey period was January 15, 
2013 through the end of February, 2013). Main survey questions were: (1) have you 
handled unused drugs since the home visits started? and (2) how did you handle 
the unused drugs? For (2), we conducted case studies by asking the pharmacists 
to choose the case that impressed them most and describe chronologically the 
unused drugs involved, the action taken, and what followed the action. Results: 
Data on 5,447 patients was collected from 1,890 pharmacies throughout Japan (col-
lection rate: 56.9%). Pharmacists handled unused drugs of 2,484 patients (45.6%). 
1,718 patients (3,593 cases) were qualified for analysis. In 2,334 cases (65%), the 
incidences of unused drugs were eliminated after pharmacists’ intervention. In 
782 cases (21.8%), unused drugs were discarded, while in 2,624 cases (73.0%), the 
number of days of drug administration was adjusted. In 21 cases (0.6%), drugs were 
both discarded and had the number of days adjusted. There were no responses 
for 166 cases (4.6%). The total price of the unused drugs that were eliminated was 
approximately 6,800,000 yen (4,000 yen/person). The top three illnesses with the 
best effects from the elimination of unused drugs were chronic respiratory failure 
(approximately 16,500 yen/person), Parkinson’s disease (approximately 5,000 yen/
person), and cancer (approximately 4,300 yen/person). ConClusions: We were 
able to confirm the economic effect of eliminating unused drugs by pharmacists’ 
home visits.
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Among seniors, 2006 to 2011
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objeCtives: This analysis examined potential risk factors for adverse drug reac-
tion (ADR)-related hospitalizations and compared seniors’ drug therapy pre-
admission and post-discharge to see whether hospitalization led to changes in 
drug therapy. Methods: This analysis used hospital discharge data from the 
Discharge Abstract Database and drug claims data from the National Prescription 
Drug Utilization Information System Database to assess potential risk factors for 
ADR hospitalizations among seniors on public drug programs in Alberta, Manitoba 
and P.E.I. Results: The number of drugs was the most significant risk factor, with 
seniors taking 15 or more drugs 6.4 times more likely than seniors taking fewer 
than 5 drugs to have been hospitalized for an ADR. Other factors associated with 
hospitalizations for ADRs were patient age and being hospitalized in the previous 
year. The relationship between new drug starts and ADR-related hospitalizations 
varied by drug class. 33.2% of seniors hospitalized for an opioid-related ADR started 
taking an opioid within 30 days of hospitalization, while only 28.2% of seniors hos-
pitalized for an anticoagulant-related ADR started an anticoagulant within a year of 
hospitalization. ConClusions: Although it is often necessary for seniors to take 
multiple drugs to manage their chronic conditions, regular medication reviews can 
help reduce the risk of adverse events including drug interactions. A high proportion 
of the hospitalizations related to anticoagulant ADRs occurred more than a year 
after starting therapy, which underscores the importance of ongoing monitoring.
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Profiling HeAltH CAre utilizAtion of elDerly versus DisAbleD 
meDiCAre DuAl eligibles: Different strokes for Different folks
Doshi J.A.1, Li P.1, Subedi P.2, Davis-Cerone M.2
1University of Pennsylvania, Philadelphia, PA, USA, 2Pfizer Pharmaceuticals, Inc., New York, NY, 
USA
objeCtives: Dual-eligibles are elderly and disabled under age 65 individuals who 
are entitled to Medicare and Medicaid. CMS has instituted a state demonstration 
program to test capitated and managed FFS financial alignment care models for 
duals. Limited research exists on the differences between the two dual subpopula-
tions – elderly and disabled, which could prove problematic for benefit design con-
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months) between an innovative product’s FDA and EMA approval. Average time to 
reimbursement in the EU5 after the EMA approval ranges from 7.0-11.2 months. 
Pharmaceutical companies need to plan ahead and submit the application dossier 
as early as possible to achieve faster access, especially for oncology products. Early 
access programmes, such as ATU in FRA and Cnn in ITA, may also be considered 
in certain countries.
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soCioeConomiC AnD HeAltH DeterminAnts AssoCiAteD WitH tHe use 
of tHe AmbulAtory AnD HosPitAl CAre serviCes Among tHe mexiCAn 
PoPulAtion
Uc-Coyoc R.O., Pérez-Reynaud A.G., Coello-Reyes L.A., Rodriguez-Díaz Ponce M.A.
Instituto Mexicano del Seguro Social, D.F, Mexico
objeCtives: Health care utilization is likely to be conditioned to socioeconomic 
factors. The aim of this study is to identify the impact of these determinants, as 
well as the health perception variables in the use of the health services in the 
Mexican population. Methods: Data from the National Health Survey 2012 was 
used to identify social, economic and health perception variables among users of 
the ambulatory and hospital care services. Statistical analysis was performed to 
test significant differences among users in relation to gender, equivalent household 
income and age data. A Probit model was used to identify and measure the impact 
of these variables on the utilization of the ambulatory care services among patients 
and a Poisson model for modelling the number of hospitalizations. Results: 8.48% 
of the population used ambulatory services during the last two weeks and 3.89% 
required hospitalization at least once during the last year. Significant statistical 
differences were observed between gender, income and age with the ambulatory 
and hospital care use. The results from the Probit model showed that men are less 
likely to use ambulatory services compared to women, as well as individuals at 
younger ages (0-9 years) (Z= 7.95). Additionally, at higher income deciles, a positive 
significant impact was found for using this service. The Poisson model revealed that 
education, employment and medical insurance are statistically significant variables 
with positive impact on the times people are hospitalized. Finally, other variables 
with a positive impact on both types of care are morbidity and the illness percep-
tion mainly when this is severe. ConClusions: In addition to the influence of 
socioeconomic and demographic factors, health perceptions among patients are 
significant determinants that explain the decision and frequency of the health care 
utilization in the Mexican population.
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QuAlity meDiCines tHrougH Cost minimizAtion
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objeCtives: Public expenditure on health on India is around 1% of GDP and 
79% expenditure in health of people is through out-of-pocket. Almost 30 % of the 
households slide into poverty due to high treatment costs and medicines. Though, 
India is considered as pharmacy for developing countries, yet due to poor regu-
latory control there is huge price variation in off-patent branded generics, even 
50 times or more and leaving affordability at the mercy of prescribers/dispens-
ers. Methods: The Government of Rajasthan (a federal State in India with popu-
lation about 70 million) has launched a scheme called Chief Minister’s Free Drug 
Distribution Scheme (CMFDDS) for providing free essential medicines to all irre-
spective of their economic status through establishing an autonomous Rajasthan 
Medical Services Corporation (RMSC). By well-defined transparent prequalification 
measures for products and suppliers, RMSC procures quality medicines through 
cost-minimization. Educational, managerial and regulatory strategies have been 
used to promote compliance by stakeholders Results: Quality essential medi-
cines are procured at unbelievable low cost compared to market retail prices, e.g. 
procurement cost / market retail prices for strip of 10 tablets of DICLOFENAC 50 
mg, ATORVASTATIN 10 mg, GLIMEPIRIDE 2 mg, and CLOPIDOGREL 75 mg are INR 
1.24/31.73, 2.98/103.74, 1.95/125.00 and 8.54/147.44 respectively (1 USD= INR 63) 
resulting an increase in access and equity with monthly patient inflow increased 
from 44,000,00 to 66,000,000 and decrease/elimination in out of pocket expenditure, 
as amount spent on medicines in 2 years is around INR 5,070,000,000 whereas mar-
ket price of these medicines would be. INR 30,000,000,000. ConClusions: Essential 
medicines are not costly but are being made expensive. By utilizing the pricing 
information of quality medicines along with transparent pooled procurement and 
proper distribution system can make free access to medicines, especially under-
served population with a strong political commitment coupled with the proper 
strategies in low resource settings.
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reAl-WorlD CliniCAl eviDenCe DeveloPment: An AnAlysis of relevAnt 
internAtionAl moDels for tHe PotentiAl imPlementAtion of suCH A 
ProgrAm in QuebeC
Bibeau J.1, Savoie M.2, Lachaine J.1
1University of Montreal, Montreal, QC, Canada, 2Montreal InVivo, Montreal, QC, Canada
objeCtives: There is a growing need for the development of real-world clinical evi-
dences, particularly in the field of health technology assessments. The objective of 
this analysis was to identify and describe the key elements for the implementation 
of a program aiming to develop real-world clinical evidences in Quebec. Methods: 
A literature review was conducted to analyze the position, progress and devel-
opment of strategies fostering risk management and development of real-world 
clinical evidences in different provinces and countries. A literature search was 
performed using electronic databases including Pubmed, Medline and Embase. 
Additional guidelines and government policies were retrieved using Google and 
Google Scholar. The following keywords, were used for search, alone or in combina-
tion: risk-sharing and product listing agreements, coverage with evidence devel-
PHP43
PrevAlenCe of PresCriPtion meDiCAtion use not CAPtureD by 
PresCriPtion ClAims DAtAbAses
Electricwala B.S., Carroll N.V.
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objeCtives: Prescription claims databases are commonly used for identifying 
patients for disease management programs, studying health outcomes and report-
ing on quality measures. A shortcoming of claims databases for these purposes is 
that they include only prescriptions that are adjudicated through insurance plans. 
Growth in the use of cash discount generic programs and the frequent use of drug 
samples suggests that an increasing number of prescriptions dispensed to insured 
consumers may not be captured on claims databases. We examined the extent to 
which prescription claims databases do not provide complete records of insured 
patients’ prescription drug use. Methods: We used the 2009 Medical Expenditure 
Panel Survey (MEPS) dataset. We included participants who purchased at least one 
prescription medication and who had prescription drug insurance for all of 2009. We 
quantified the extent to which insured patients used drug samples, drugs paid for 
by cash only, and/or discount generics. We measured the numbers of prescriptions 
in each of these categories and the numbers of consumers who had at least one 
prescription in each category. We reported descriptive statistics. Results: A total of 
75.1% of the U.S. non-institutionalized civilian population was insured for prescrip-
tion drugs. Of the total number of prescriptions dispensed to insured consumers, at 
least 0.8% were drug samples and 23.3 % were paid for by cash, of which 11.3% were 
potentially discount generics. Additionally, 11.6 % of insured consumers received 
at least one sample medication, 68.0% paid for at least one of their prescribed 
medications by cash, of which 42.5% used at least one potential discount generic 
product. ConClusions: Our results indicate that drug samples do not contribute 
substantially to the problem of missing prescription data on claims databases. On 
the other hand, substantial number of prescriptions, paid for by cash and discount 
generics, may be missing from these databases.
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imPACt of Drug reimbursement moDAlities on treAtment ADHerenCe 
in PAtients CovereD by PrivAte Drug insurAnCe
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objeCtives: To compare adherence to prescribed medications between patients 
with differed and those with immediate reimbursement at the point of service 
among Quebecers (Canada) with private drug insurance. Methods: A retrospec-
tive cohort was constructed by selecting patients aged 18-64 years with private 
drug insurance from the reMed database between March 2008 and December 2012. 
An algorithm was developed to assess the patient’s reimbursement modality, i.e. 
the drug cost covered by the insurance company is reimbursed immediately at the 
point of service (immediate reimbursement) or at a later time (differed reimburse-
ment). Adherence was measured with the proportion of days covered (PDC) over one 
year for new users of the five most dispensed classes of medications, i.e. statins, 
proton pump inhibitors, thyroid hormones, antidepressants, and antihypertensive 
medications. Linear regression models were used to estimate the adjusted mean 
difference of the PDC between the two groups for each drug class. Results: The 
cohort included 6,494 patients with immediate and 1,950 patients with differed 
drug reimbursement. More than 40% of patients were 35-49 years, 26% were men 
and 85% were past or non-smokers. The mean PDC was 79.9 % for patients with 
immediate reimbursement and 89.3 % for patients with differed reimbursement 
among new users of statins. Corresponding figures were 48.3% and 45.1% for new 
users of proton pump inhibitors, 84.7% and 84.8% for new users of thyroid hormones, 
67.1% and 66.8% for new users of antidepressants, and 68.4% and 73.5% for new 
users of antihypertensive medications. The results of the linear regression analyses 
showed no significant differences between patients with immediate and differed 
drug reimbursement. ConClusions: Patient’s adherence was low for several drug 
classes but appeared to be unaffected by differed reimbursement. The short period 
of time between the purchase of the medication and the reimbursement by the 
insurer might explain the results.
HeAltH CAre use & PoliCy stuDies – equity & Access
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DifferenCe betWeen uniteD stAtes AnD eu AutHorisAtion timelines 
AnD time to reimbursement in tHe eu5
Sun D., Beckerman R.
CBPartners, New York, NY, USA
objeCtives: The purpose of this study was to estimate the time difference between 
the FDA and EMA approvals, as well as time to reimbursement in the UK, GER, 
FRA, ESP and ITA after EMA approval. Methods: 32 high-cost drugs that were 
approved by both the FDA and EMA in 2011-2013 were assessed. Two-thirds of the 
sample were oncology drugs; the remaining one third included drugs treating other 
specialty diseases. Out of 32 drugs, 17 have obtained reimbursement from all EU5 
countries. Time of reimbursement was defined as the date of publication of SMC 
guidelines in SCT, NICE Final Appraisal Determination in ENG, CT decision in FRA, 
G-BA decision in GER, AIFA decision in ITA and AEMPS decision in ESP. Results: 
The average time difference between the FDA and EMA approvals (USA-EU approval 
interval) was 5.9 months (standard deviation (SD) 5.2 months), similar to the median 
USA-EU approval interval (6 months). The average time to reimbursement after EMA 
approval varies from 211 days in SCT (SD 75.9 days) to 336 days in ESP (SD 203 days). 
On average, the USA-EU approval interval for oncology drugs was almost twice as 
long as for non-oncology drugs (7.0 vs. 3.8 months), but there was minimal differ-
ence in time to reimbursement for oncology versus non-oncology drugs in the EU5, 
except in ESP, where the reimbursement decision for non-oncology drugs was 112 
days faster than for oncology drugs. ConClusions: There is still a long gap (5.9 
